BLU-667 Controls RET-Altered Thyroid Cancers.
The experimental RET inhibitor BLU-667 appears safe and effective in patients with RET-altered thyroid cancers, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In the phase II ARROW trial, the drug elicited responses in 56% of patients with advanced RET-mutated medullary thyroid cancer and five out of six patients with papillary thyroid cancer and was associated with mild side effects.